The Industry Standard: TAM, SAM, and SOM

TAM (Total Addressable Market) is the full global opportunity if there were no constraints: it establishes that the problem justifies building a company, and it is never an operational target. SAM (Serviceable Addressable Market) is the portion your solution can realistically serve given its capabilities, clinical context, regulatory access, and geography: capability, not strategy. SOM (Serviceable Obtainable Market) is the revenue calculation derived from your Target Market definition: what that market is worth in near-term capturable revenue. SOM is an output of the Target Market definition; it does not define it.

Why Sizing Alone Is Not Enough

TAM, SAM, and SOM size an opportunity; they do not choose one. "The colorectal surgery market is $2B and we will capture 5%" is a revenue guess, not a strategy. The strategic work is choosing where to build, and that requires two further definitions.

Target Market: the First Place You Build a Real Business

The Target Market is the specific, bounded segment, geography, and use case where you intend to build your first sustainable business. It must be defined narrowly enough to be actionable: a specific user group, clinical context, and institutional setting, not "hospitals in Europe." The Target Market canvas is the reference point everything else is assessed against.

Beachhead Market: Proving You Can Win the Target Market

The Beachhead is the initial wedge within the Target Market: intentionally narrow, chosen as the starting point for early evidence, credibility, and momentum. Its purpose is not revenue; it is proof that transfers. A strong beachhead has an urgent need, accessible stakeholders, a concentrated and winnable segment, referenceable early adopters, an identifiable clinical champion, an existing reimbursement pathway, a navigable approval process, and a defined regulatory path compatible with your runway.

Why healthcare is different. In most industries, an initial market is a cheap experiment: enter, learn, and abandon it if it disappoints. In healthcare that mindset is a mistake. The regulatory clearances, reimbursement pathways, clinical evidence, and user and buyer relationships you build in the beachhead are slow and expensive to create, and they are the assets that must transfer to the Target Market. A beachhead chosen casually can be won completely and still leave you stranded: wrong geography for your regulatory strategy, wrong payor context for your reimbursement model, wrong evidence for the buyers who come next. Choose the beachhead for what it enables. A successful beachhead that is a bridge to nowhere is still nowhere.

The beachhead is never evaluated in isolation. Its value lies in what it enables: evidence that clinicians adopt, institutions support, and the model works, in ways the rest of the Target Market will find credible. A beachhead that succeeds but teaches you nothing transferable was the wrong beachhead.

How These Concepts Work Together

Define them in this order. SAM: where could this product realistically be used? Target Market: where will we focus to build a sustainable business? Beachhead: where within the Target Market will we start? SOM: what is the near-term capturable revenue from the Target Market? TAM frames the long-term vision for investors; the pathway from Beachhead through Target Market is what they actually fund.

Concrete Example: a Medical Device Starting in Spain

A ventilation training device company defines its SAM as simulation-based clinical training programs in the EU. Its Target Market: public teaching hospitals in Spain and Portugal running ICU and PICU simulation programs. Its Beachhead: PICU simulation faculty at high-volume public teaching hospitals in Barcelona and Madrid with named clinical champions and existing simulation budgets. SOM is then calculated from the Target Market definition: institutions, eligible training sessions per year, achievable adoption, price per session. Every number in that chain is a testable claim, and the beachhead exists to start testing them.

Final Perspective

Investors do not fund a TAM. They fund a credible pathway: a beachhead you can demonstrably win, a target market it demonstrably leads to, and evidence that the lessons transfer. Define markets so that every claim in the chain can be tested, and the market definition becomes an asset rather than a slide.